Find here all our blog posts tagged with: MDR.

Overlapping translucent rings symbolizing intersecting regulatory frameworks over a data network, representing convergence without any visible text.

Agentic AI in Clinical Trials Isn't Exempt From High-Risk Classification

Agentic AI tools for trial design look administrative, but EU AI Act and MDR overlap rules can pull them into conformity assessment regardless of vendor intent.

Abstract image of two intersecting light arcs, one medical and one technological in form, with a visible unaligned gap between them.

The Change-Control Gap Between MDR and the AI Act

Predetermined change control plans reveal the specific reconciliation gap between MDR/IVDR certification and EU AI Act obligations for adaptive medical algorithms.

A human hand and a robotic arm converging toward a single point of light in a clinical setting, symbolizing parallel evaluation of clinicians and AI devices.

The Doctor Test for AI Devices

FDA's move toward clinician-style, ongoing assessment of AI-enabled devices reshapes what counts as durable evidence, ahead of any final guidance.

Two diverging highway lanes at dusk, one illuminated and one dim, leading toward an empty horizon.

Two New Fast Lanes for AI Devices, No New Evidence Standard

EU and FDA are both building faster pathways for AI medical devices, but neither has defined what evidence should earn a device the fast lane.

An hourglass with mechanical device fragments suspended in falling sand, symbolizing a regulatory deadline that has shifted but not disappeared.

The EU AI Act Extension Is Not the Relief It Looks Like

Brussels pushed back the high-risk AI Act deadline for regulated medical devices, but MDR and IVDR certification bottlenecks did not move with it.

Two overlapping translucent regulatory frameworks depicted as intersecting glass panels above a European skyline.

Europe's AI Act and MDR Collide, and MedTech Wants a Rewrite

European MedTech is lobbying to revise how the EU AI Act and MDR/IVDR interact, and regulated buyers should build to the stricter combination now, not wait for the fix.

Two shifting translucent glass panels overlapping in a clinical white laboratory space, symbolizing two regulatory frameworks being revised in parallel.

Europe's AI Act and MDR Are Being Rewritten at the Same Time

European regulators are revising the AI Act and MDR simultaneously, leaving life sciences compliance teams no stable baseline to build against.

A multi-layered glass hourglass with sand suspended between tinted panes, symbolizing a regulatory grace period built from stacked compliance layers.

The Extended Clock Is Not a Reprieve

The EU AI Act's delayed enforcement dates for medical device AI give sponsors more runway, but only if they use it to align MDR/IVDR and AI Act evidence now.

Two parallel corridors of differing length in a clinical facility, symbolizing divergent regulatory paths for medical device approval.

Europe's New Fast Lane for Breakthrough AI Devices Comes With No Governance Shortcut

The EU's new Breakthrough Devices framework under MDR/IVDR speeds review timelines but leaves AI governance obligations fully intact.

Two interlocking translucent gears symbolizing overlapping regulatory systems for clinical AI in Europe

Europe's Dual Certification Trap for Clinical AI

AI systems that influence clinical decisions can trigger MDR and EU AI Act obligations at once, and the Digital Omnibus timeline does not change that exposure.

Rigid glass panels warping into fluid shapes under soft internal light, symbolizing static regulatory categories under strain from adaptive systems.

Static Categories, Adaptive Systems: The Real Fault Line in AI Device Review

FDA and EU sandbox pilots for agentic AI are one symptom of a broader breakdown in static regulatory categories, and buyers should treat both the hype and the early-engagement tradeoffs with equal scrutiny.

Two interlocking clock gears of different sizes photographed in dim industrial light, symbolizing misaligned regulatory timelines.

The FDA Is Still Asking Questions. Brussels Already Moved Its Clock Once.

FDA's open genAI comment period and the EU's already-shifted AI Act deadlines argue for building the shared lifecycle core, not betting on either jurisdiction's paperwork.

Hands fitting together translucent glass gears on a dark table, symbolizing the mechanics of valuing regulatory governance in a life sciences acquisition.

In HealthTech M&A, AI Governance Is Now a Line Item on the Term Sheet

Buyers in HealthTech and MedTech deals are pricing AI governance maturity directly into valuation, not treating it as a closing condition.

Abstract layered forms contrasting a fixed structure with a fluid, shifting one to evoke static documentation versus adaptive systems.

MedTech Diligence Now Has to Read Change Plans, Not Just Technical Files

AI-enabled devices are adding predetermined change control plans to MDR/IVDR technical files, and buyers evaluating MedTech targets need to diligence both.

Aerial view of a river forking into two channels, symbolizing diverging US and EU regulatory paths for AI medical devices

The PCCP Illusion: Why US Speed Doesn't Buy EU Clearance

FDA's finalized change control pathway lets AI devices update without new submissions, but the EU AI Act demands continuous oversight that PCCPs were not built to satisfy.

A glass sphere with an internal geometric lattice lit differently on each half, symbolizing one AI model interpreted under two regulatory regimes.

The PCCP Gap: FDA Lets AI Models Change, Europe Asks Which Model You Meant

FDA's finalized change control plans let AI-enabled devices update without new submissions, but EU classification law may treat the same update as a new device.

A river delta splitting into two divergent channels, symbolizing diverging regulatory paths for AI-enabled medical devices.

The Quality System Nobody Rebuilt Yet

FDA's living PCCP model for AI-enabled devices demands continuous evidence trails that most design control systems were never built to produce.